- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT01223365
Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time
A 12-Month, Open-Label Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours in Patients Who Require Opioid Treatment for an Extended Period of Time
Обзор исследования
Подробное описание
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
Alabama
-
Mobile, Alabama, Соединенные Штаты
- Horizon Research Group, LLC
-
-
California
-
Anaheim, California, Соединенные Штаты
- Physician Alliance Research Center
-
Beverly Hills, California, Соединенные Штаты
- Adam D. Karns, MD
-
Buena Park, California, Соединенные Штаты
- Associated Pharmaceutical Research Center, Inc.
-
Burbank, California, Соединенные Штаты
- Providence Clinical Research
-
Fresno, California, Соединенные Штаты
- Research Center of Fresno, Inc.
-
Laguna Hills, California, Соединенные Штаты
- Pacific Coast Pain Management Center
-
Laguna Hills, California, Соединенные Штаты
- South Orange County Surgical Medical Group
-
San Diego, California, Соединенные Штаты
- Accelovance, Inc.
-
Valley Village, California, Соединенные Штаты
- Bayview Research Group, LLC
-
-
Florida
-
Clearwater, Florida, Соединенные Штаты
- Clinical Research of West Florida, Inc.
-
DeLand, Florida, Соединенные Штаты
- Avail Clinical Research, LLC
-
Orlando, Florida, Соединенные Штаты
- Compass Research, LLC
-
Sarasota, Florida, Соединенные Штаты
- Sarasota Pain Medicine Research LLC
-
Weston, Florida, Соединенные Штаты
- Gold Coast Research LLC
-
-
Georgia
-
Marietta, Georgia, Соединенные Штаты
- Drug Studies America
-
Marietta, Georgia, Соединенные Штаты
- Georgia Institute for Clinical Research, LLC
-
Marietta, Georgia, Соединенные Штаты
- Taylor Research, LLC
-
Newnan, Georgia, Соединенные Штаты
- Better Health Clinical Research, Inc.
-
-
Illinois
-
Bloomington, Illinois, Соединенные Штаты
- Millennium Pain Center
-
-
Indiana
-
Indianapolis, Indiana, Соединенные Штаты
- Rehabilitation Associates of Indiana
-
-
Kansas
-
Overland Park, Kansas, Соединенные Штаты
- International Clinical Research, Inc.
-
-
Kentucky
-
Crestview Hills, Kentucky, Соединенные Штаты
- Community Research
-
-
Louisiana
-
Shreveport, Louisiana, Соединенные Штаты
- Willis Knighton River Cities Clinical Research Center
-
-
Maryland
-
Pikesville, Maryland, Соединенные Штаты
- MidAtlantic Pain Medicine Center
-
-
Massachusetts
-
Brockton, Massachusetts, Соединенные Штаты
- Beacon Clinical Research, LLC
-
-
Missouri
-
Florissant, Missouri, Соединенные Штаты
- HealthCare Research
-
Saint Louis, Missouri, Соединенные Штаты
- Sundance Clinical Research, LLC
-
-
Nebraska
-
Omaha, Nebraska, Соединенные Штаты
- Meridian Clinical Research
-
-
Nevada
-
Las Vegas, Nevada, Соединенные Штаты
- Clinical Research Center Of Nevada
-
-
New Jersey
-
Voorhees, New Jersey, Соединенные Штаты
- Advanced Pain Consultants
-
-
New York
-
Williamsville, New York, Соединенные Штаты
- Upstate Clinical Research Associates
-
-
North Carolina
-
Raleigh, North Carolina, Соединенные Штаты
- Wake Research Associates
-
-
Ohio
-
Cincinnati, Ohio, Соединенные Штаты
- Sterling Research Group, Ltd.
-
Columbus, Ohio, Соединенные Штаты
- Columbus Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Соединенные Штаты
- SP Research
-
-
Oregon
-
Eugene, Oregon, Соединенные Штаты
- Pain Research of Oregon
-
Portland, Oregon, Соединенные Штаты
- Summit Research Network Inc.
-
-
Pennsylvania
-
Downingtown, Pennsylvania, Соединенные Штаты
- Brandywine Clinical Research
-
Feasterville-Trevose, Pennsylvania, Соединенные Штаты
- AMH Feasterville Family Health Care Center
-
Tipton, Pennsylvania, Соединенные Штаты
- Tipton Medical and Diagnostic Center
-
West Reading, Pennsylvania, Соединенные Штаты
- Clinical Research Center of Reading, LLP
-
-
Rhode Island
-
Warwick, Rhode Island, Соединенные Штаты
- Omega Medical Research
-
-
South Carolina
-
Greenville, South Carolina, Соединенные Штаты
- Greenville Pharmaceutical Research
-
North Charleston, South Carolina, Соединенные Штаты
- Trident Institute of Medical Research, LLC
-
Spartanburg, South Carolina, Соединенные Штаты
- S. Carolina Pharmaceutical Research
-
-
Texas
-
Dallas, Texas, Соединенные Штаты
- KRK Medical Research
-
Dallas, Texas, Соединенные Штаты
- Radiant Research
-
Dallas, Texas, Соединенные Штаты
- Renaissance Clinical Research & Hypertension of Texas, PLLC
-
Houston, Texas, Соединенные Штаты
- MedStar Clinical Research
-
San Angelo, Texas, Соединенные Штаты
- Benchmark Research
-
Sugar Land, Texas, Соединенные Штаты
- DCT-Sugarland, LLC dba Discovery Clinical Trials
-
Waco, Texas, Соединенные Штаты
- Hillcrest Family Health Centers
-
-
Utah
-
Orem, Utah, Соединенные Штаты
- Aspen Clinical Research, LLC
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- The patient must be willing and able to successfully self-administer the study drug, comply with study restrictions, and return to the clinic for scheduled study visits as specified in this protocol.
- The patient has either completed Cephalon study 3079 or has chronic pain of at least 3 months duration prior to entering this study associated with any of the following conditions: diabetic peripheral neuropathy, postherpetic neuralgia, traumatic injury, complex regional pain syndrome, back pain, neck pain, osteoarthritis, or rheumatoid arthritis. Patients with other painful conditions may qualify for the study with permission from the Cephalon medical monitor or designee.
- Those patients who completed the 12-week, double-blind, placebo-controlled, randomized study (study 3079) and are willing to re-titrate study drug to an effective dose of hydrocodone extended-release tablets are eligible to enter this study.
- The patient is able to speak English, willing to provide written informed consent, and sign a written opioid agreement, to participate in this study.
- The patient is 18 through 80 years of age (inclusive) at the time of entering this or the previous study (study 3079).
- Women of childbearing potential (not surgically sterile or 2 years postmenopausal), must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study, and have a negative pregnancy test at screening.
Exclusion Criteria:
- Patients who were enrolled in study 3079 but did not complete the 12-week, double-blind, placebo-controlled, randomized study may not be enrolled into this study.
- The patient has known or suspected hypersensitivities, allergies, or other contraindications to the study drug or its excipients.
- The patient has a recent history (within 5 years) or current evidence of alcohol or other substance abuse.
- The patient has a medical or psychiatric condition/disease that, in the opinion of the investigator, would compromise collected data.
- The patient is taking a total (i.e., including around-the clock [ATC] and rescue medications) of more than 135 mg/day of oxycodone or equivalent for 14 days prior to screening.
- The patient has a history of suicidality.
- The patient has a diagnosis of chronic headache or migraine as the primary painful condition under study.
- The patient is expected to have surgery during the study and it is anticipated that the surgery will alleviate the patient's pain.
- The patient is pregnant or lactating.
- The patient has active malignancy.
- The patient has human immunodeficiency virus (HIV).
- In the judgment of the investigator, the patient has any clinically significant deviation from normal in the physical examination and/or clinical laboratory test values.
- The patient has cardiopulmonary disease that would, in the opinion of the investigator, significantly increase the risk of treatment with potent synthetic opioids.
- The patient has participated in a study involving an investigational drug in the previous 30 days (excluding those who participated in study 3079).
- The patient has received a monoamine oxidase inhibitor (MAOI) within 14 days before the first treatment with study drug.
- The patient has any other medical condition or is receiving concomitant medication/therapy (e.g., regional nerve block) that would, in the opinion of the investigator, compromise the patient's safety or compliance with the study protocol, or compromise collected data.
- The patient is involved in active litigation in regard to the chronic pain currently being treated.
- The patient has a positive urine drug screen (UDS) for an illicit substance or medication not prescribed by the physician currently treating the chronic pain.
- The investigator feels that the patient is not suitable for the study.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Экспериментальный: Hydrocodone ER
Participants were titrated (or re-titrated for roll-over participants) at escalating dosages of extended-release hydrocodone tablets at dosages of 15, 30, 45, 60, or 90 mg orally every 12 hours until deemed successful for managing their pain during the open-label titration period.
Once a successful dose was identified, participants entered the 52 week open-label treatment period in which hydrocodone ER was administered at the successful dose (15, 30, 45, 60, or 90 mg) every 12 hours.
|
Hydrocodone bitartrate extended-release tablets were administered at doses of 15, 30, 45, 60, and 90 mg orally every 12 hours.
During the open-label titration period, doses were adjusted until a stable pain control was achieved.
In general, the dose of hydrocodone extended release tablets could be adjusted for efficacy or tolerability, as necessary, at any time during the open-label treatment period; however, participants were required to visit the study center before increasing the dose of study drug.
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Participants With Adverse Experiences
Временное ограничение: Day 1 of open-label titration period - Week 52 of the open-label treatment period
|
An adverse event (AE) was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug.
Relation of AE to treatment was determined by the investigator.
Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
|
Day 1 of open-label titration period - Week 52 of the open-label treatment period
|
Participants With Potentially Clinically Significant (PCS) Abnormal Laboratory Values During the Open-Label Treatment Period by Participant Status
Временное ограничение: Day 1 - Week 52 of the open-label treatment period
|
Data represents participants with PCS abnormal serum chemistry, hematology and urinalysis values. Significance criteria:
|
Day 1 - Week 52 of the open-label treatment period
|
Participants With Potentially Clinically Significant Abnormal Vital Signs Values by Participant Status
Временное ограничение: Day 1 of open-label titration period - Week 52 of the open-label treatment period
|
Data represents participants with potentially clinically significant (PCS) vital sign values. Significance criteria
|
Day 1 of open-label titration period - Week 52 of the open-label treatment period
|
Shifts in Electrocardiogram (ECG) Findings From Baseline to Overall Study by Participant Status
Временное ограничение: Baseline for new participants was between Day -7 and -14 (the study 3080 screening visit); baseline for rollover participants was the last ECG in study 3079. During study ECGs were performed on weeks 24 and 52 of the open-label treatment period
|
A 12-lead ECG was conducted at screening, week 24, and week 52 or at the last postbaseline observation. For rollover participants, the ECG performed at the final visit of study 3079 served as the 1st ECG in study 3080. A qualified physician was responsible for interpreting the ECG. Any ECG finding that was judged by the investigator as a clinically meaningful change (worsening) compared with baseline was considered an adverse event. For overall results, the worst postbaseline finding for the participant was summarized. Results below are formatted as Baseline ECG result - Overall ECG result. |
Baseline for new participants was between Day -7 and -14 (the study 3080 screening visit); baseline for rollover participants was the last ECG in study 3079. During study ECGs were performed on weeks 24 and 52 of the open-label treatment period
|
Participants With Clinically Significant (CS) Hearing Changes From Baseline in Pure Tone Audiometry Test Results by Patient Status
Временное ограничение: Baseline for new participants was between Day -7 and -14 (study 3080 screening visit); baseline for rollover participants was the baseline test in study 3079. During study covers both open-label titration and 52-week treatment periods
|
Pure tone audiometry was performed by trained personnel.
During the test, the patient wore headphones and was seated in a quiet room; trained personnel manipulated the audiometry equipment to test the patient's hearing.
For serial audiograms, the criteria for a clinically significant (CS) hearing change were based on the guidance from the American Speech-Language Hearing Association (ASHA) 1994 (Konrad-Martin et al 2005).
These criteria included the following: greater than 20 decibels (dB) pure tone threshold shift at 1 frequency; greater than 10 dB shift at 2 consecutive test frequencies; or threshold response shifting to "no response" at 3 consecutive test frequencies.
|
Baseline for new participants was between Day -7 and -14 (study 3080 screening visit); baseline for rollover participants was the baseline test in study 3079. During study covers both open-label titration and 52-week treatment periods
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Participant Global Assessment (PGA) of the Method of Pain Control by Participant Status
Временное ограничение: Baseline for new participants was Day 1, i.e. the first day of open-label titration. Baseline for rollover participants was the baseline in study 3079. Week 4 (end of titration, start of open-label treatment), Week 52, last visit up to Week 52
|
The PGA of the method of pain control consisted of a asking patients a single question to assess their method of pain control during the previous 24 hours as either poor, fair, good, or excellent (Rothman et al 2009).
|
Baseline for new participants was Day 1, i.e. the first day of open-label titration. Baseline for rollover participants was the baseline in study 3079. Week 4 (end of titration, start of open-label treatment), Week 52, last visit up to Week 52
|
Participants by Risk Category for Aberrant Drug Misuse Based on the Total Score in the Screener and Opioid Assessment for Patients With Pain - Revised (SOAPP-R)
Временное ограничение: End of Open-label Titration Period. Weeks 4 and 24 of the Open-label Treatment Period
|
SOAPP-R is a clinician-rated scale used to assess each patient's risk of developing aberrant drug use behaviors while on long term opioid therapy. SOAPP-R consists of 24 questions that address 8 concepts: substance abuse history, medication related behaviors, antisocial behaviors/history, psychosocial problems, psychiatric history, physician patient relationship factors, emotional attachment to pain medications, and personal care and lifestyle issues (Butler et al 2008). Each question is answered using a 5 point Likert-like scale, with 0=never, 1=seldom, 2=sometimes, 3=often, and 4=very often for a total range of 0-96. The higher the overall score, the greater the probability the patient is at risk for displaying aberrant behaviors consistent with drug use. An overall score of 18 or higher is considered positive for predicting aberrant drug related behavior, therefore the reported risk categories are
|
End of Open-label Titration Period. Weeks 4 and 24 of the Open-label Treatment Period
|
Addiction Behavior Checklist (ABC) Total Scores During Both the Open-Label Titration and Open-Label Treatment Periods by Participant Status
Временное ограничение: Baseline for new participants was Day 1 of open-label titration; rollover participants baseline was in study 3079. End of Open-label Titration: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 40, 44, 48, 52 and last visit up to week 52
|
The ABC was a clinician rated scale that consisted of a brief (21 item) questionnaire designed to track behaviors characteristic of addiction related to prescription opioid medications in chronic pain populations.
Items were focused on observable behaviors noted both during and between clinic visits.
Each affirmative response was counted as 1 point, and points were added to calculate the total score.
All but 1 of the 21 items (the provider's impression) was used in calculating the total score, consequently resulting in scores ranging from 0 to 20 (0=no addiction-related behaviors seen and higher scores indicating an increasing number of addition-related behaviors seen).
Participants with a total score of 3 or greater were classified as exhibiting inappropriate opioid use during the study.
|
Baseline for new participants was Day 1 of open-label titration; rollover participants baseline was in study 3079. End of Open-label Titration: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 40, 44, 48, 52 and last visit up to week 52
|
Current Opioid Misuse Measure (COMM) Scores During Both the Open-Label Titration and Open-Label Treatment Periods by Participant Status
Временное ограничение: Baseline for new participants was Day 1 of open-label titration; rollover participants baseline was in study 3079. End of Open-label Titration Period. Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 40, 44, 48, 52 and last visit up to week 52
|
The COMM was a clinician-rated scale developed as a brief self-report measure of current aberrant drug-related behavior for patients with chronic pain who were already on long-term opioid therapy.
A total score was calculated as the sum of the 17 questions.
The total score ranged from 0 to 68.
A score of 0 indicates no aberrant drug-related behaviors were seen.
Patients with a total score of 9 or greater were classified as exhibiting aberrant drug-related behavior.
|
Baseline for new participants was Day 1 of open-label titration; rollover participants baseline was in study 3079. End of Open-label Titration Period. Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 40, 44, 48, 52 and last visit up to week 52
|
Соавторы и исследователи
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- C33237/3080
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования Hydrocodone ER
-
RVL Pharmaceuticals, Inc.Osmotica Pharmaceutical US LLCОтозванРассеянный склероз | СпермаСоединенные Штаты
-
HealthPartners InstituteПрекращено
-
Uppsala UniversityРекрутингСДВГ | Регуляция эмоций | Синдром дефицита внимания с гиперактивностьюШвеция
-
Jewish General HospitalРекрутингЧрезвычайные ситуации | Продолжительность пребыванияКанада
-
Asieris Pharmaceuticals (AUS) Pty Ltd.Завершенный
-
Member Companies of the Opioid PMR ConsortiumПрекращеноРасстройства, связанные с опиоидами | Злоупотребление наркотиками | Опиатная зависимость | Злоупотребление наркотикамиСоединенные Штаты
-
University Hospital Inselspital, BerneОтозванКрасная волчанка, кожнаяШвейцария
-
Columbia UniversityBiolase IncАктивный, не рекрутирующийПериимплантитСоединенные Штаты
-
National Institute of Mental Health (NIMH)ЗавершенныйФармакокинетика | ВзрослыйСоединенные Штаты
-
University of MiamiОтозван